CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
调控肿瘤微环境以增强癌症免疫治疗的多功能纳米复合物
英文原题：Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy.
查看英文原题
Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年，癌症免疫治疗在恶性肿瘤治疗中迅速发展。免疫检查点阻断和嵌合抗原受体细胞疗法（CAR-T）对血液肿瘤和实体瘤均显示出显著活性。然而，免疫抑制性肿瘤微环境（TME）会削弱现有免疫疗法的总体疗效。纳米材料的设计和工程技术进步为调节TME开辟了新途径。通过整合不同分子的协同功能，纳米复合材料有望克服免疫抑制并诱发强效免疫应答。本文综述纳米医学应用的最新进展，重点讨论用于调节TME、增强癌症免疫治疗的特定纳米复合材料，并介绍目前进入临床阶段的癌症免疫治疗纳米复合材料概况。
展开英文摘要原文
Cancer immunotherapy has gained momentum for treating malignant tumors over the past decade. Checkpoint blockade and chimeric antigen receptor cell therapy (CAR-T) have shown considerable potency against liquid and solid cancers.
However, the tumor microenvironment (TME) is highly immunosuppressive and hampers the effect of currently available cancer immunotherapies on overall treatment outcomes. Advancements in the design and engineering of nanomaterials have opened new avenues to modulate the TME. Progress in the current nanocomposite technology can overcome immunosuppression and trigger robust immunotherapeutic responses by integrating synergistic functions of different molecules.
We will review recent advancements in nanomedical applications and discuss specifically designed nanocomposites modulating the TME for cancer immunotherapy.
In addition, we provide information on the current landscape of clinical-stage nanocomposites for cancer immunotherapy.
论文信息
- 作者
- Sharma P、Otto M
- 单位
- Department of Child Health, University of Arizona College of Medicine-Phoenix, ABC1 Building, 425 N 5th Street, Phoenix, AZ, 85004, USA.United States
- 文献类型
- 综述
- 期刊
- Bioactive materials2024 Jan
- 原文标识
- PubMed 37701452 · DOI 10.1016/j.bioactmat.2023.08.022
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →